Table. 2.

Comparison of the ZEST and SPS

Characteristic ZEST SPS
Study population 50-59 yr with VZV infection ≥ 60 yr with VZV infection
n = 22,439 n = 38,546
Median follow-up 1.3 yr (up to 2 yr) 3.12 yr
HZ risk reduction Overall: 69.8% Overall: 51.3%
60-69 yr: 63.9%
≥ 70 yr: 37.6%
PHN risk reduction NA 66.5%
Vaccine-related serious adverse events n = 1 (vs. n = 0 in placebo) n = 2 (vs. n = 3 in placebo)

ZEST: Zoster Vaccine Efficacy and Safety Trial, SPS: Shingles Prevention Study, HZ: herpes zoster, PHN: postherpetic neuralgia, VZV: varicella zoster virus, NA: not assessed.

Korean J Pain 2020;33:201~207 https://doi.org/10.3344/kjp.2020.33.3.201
© Korean J Pain